I-SNAP: Immunotherapy Standardized Nursing Assessment Protocol With Keri Mahoney, JD, RN, CPHRM

With the rapidly increasing use of immunotherapy in the treatment of some cancers, oncology nurses need to be comfortable and knowledgeable in administering immunotherapeutic treatments and assessing patients for immune-related adverse events. In this interview with i3 Health, Keri Mahoney, JD, RN, CPHRM, discusses her immunotherapy educational intervention for nurses, which she presented in a poster at the Oncology Nursing Society (ONS) 44th Annual Congress in Anaheim, California. What was the ...
Continue reading

Preparing Nurses to Manage CAR T-Cell Therapy Adverse Events With Lindsey Bashaw, RN

Chimeric antigen receptor (CAR) T-cell therapy is a new form of immunotherapy in which a patient's own T cells are collected and genetically altered to target cancer cells. Although CAR T-cell therapy has shown encouraging clinical trial results in patients with acute lymphoblastic leukemia and B-cell lymphomas, they are associated with severe adverse events such as cytokine release syndrome, neurotoxicity, tumor lysis syndrome, and graft-versus-host disease. Many of the patients who receive CAR...
Continue reading

New Insights into the Precise Function of CAR T Cells

​ Chimeric antigen receptor (CAR) T-cell therapy modifies the patient's own T cells, otherwise known as natural killer cells or cytotoxic T lymphocytes, to enable the T cells to recognize and eliminate a target molecule, CD19, on the cancerous cells. While this form of immunotherapy has great potential in treating B-cell malignancies, relapse does occur in some patients. Researchers have gained new insights into the outcome and dynamics of CAR T-cell interactions in different anatomical sites, r...
Continue reading

First-Line Atezolizumab Approved: Extensive-Stage SCLC

​ The FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.) in combination with carboplatin and etoposide as first-line treatment for patients with extensive-stage (ES) small cell lung cancer (SCLC). This is the first immunotherapy-based combination to be approved in the initial treatment of ES-SCLC. Extensive-stage SCLC has spread widely throughout the lung, to the other lung, to lymph nodes on the other side of the chest, to the fluid around the lung, or to other areas in the body, such ...
Continue reading

Antibody-Drug Conjugate Is Powerful Against Neuroblastoma

Researchers at the Cancer Center of Children's Hospital of Philadelphia (CHOP) have developed an antibody-drug conjugate (ADC) that is powerfully effective against mouse models of neuroblastoma expressing wild-type and mutant anaplastic lymphoma kinase (ALK). Neuroblastoma, a cancer of the peripheral nervous system typically found in children younger than 5, is the third most common pediatric cancer and the most common cancer in infants. It accounts for over 10% of all childhood cancer-related d...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.